Long-Term ACE Inhibitor/ARB Use Is Associated with Severe Renal Dysfunction and Acute Kidney Injury in Patients with severe COVID-19: Results from a Referral Center Cohort in the North East of France.
Fiche publication
Date publication
juillet 2020
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GUEANT Jean-Louis, Dr NAMOUR Bernard, Pr THILLY Nathalie, Dr OUSSALAH Abderrahim
Tous les auteurs :
Oussalah A, Gleye S, Clerc Urmes I, Laugel E, Callet J, Barbé F, Orlowski S, Malaplate C, Aimone-Gastin I, Caillierez BM, Merten M, Jeannesson E, Kormann R, Olivier JL, Rodriguez-Guéant RM, Namour F, Bevilacqua S, Losser MR, Levy B, Kimmoun A, Gibot S, Thilly N, Frimat L, Schvoerer E, Guéant JL
Lien Pubmed
Résumé
In patients with severe COVID-19, data are scarce and conflicting regarding whether chronic use of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) influences disease outcomes. In patients with severe COVID-19, we assessed the association between chronic ACEI/ARB use and the occurrence of kidney, lung, heart, and liver dysfunctions and the severity of the inflammatory reaction as evaluated by biomarkers kinetics, and their association with disease outcomes.
Mots clés
SARS-CoV-2, acute kidney injury, angiotensin receptor blocker, angiotensin-converting enzyme inhibitor, severe COVID-19
Référence
Clin. Infect. Dis.. 2020 Jul 5;: